Dr. Apurva C. Mehta, MD

Dr. Mehta practices at TriHealth's Good Samaritan Hospital in Cincinnati, Ohio, part of TriHealth.

Dr. Mehta's NPI, 1245211655, was assigned on November 11, 2005. Dr. Mehta holds Ohio license 35.081652.

Dr. Mehta's primary practice is TriHealth's Good Samaritan Hospital, at 375 Dixmyth Avenue, Cincinnati, OH 45220 in Hamilton County. The practice phone is (513) 862-2601.

Dr. Mehta's primary practice is TriHealth's Good Samaritan Hospital in Cincinnati, Ohio, part of TriHealth. Dr. Mehta is also affiliated with Bethesda North Hospital. The medical group on file is TriHealth. Dmand AI also links Dr. Mehta to 3 more group practices and clinics, 2 medical groups and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Mehta's licenses on file in 2 states: Ohio and Kentucky.

CMS data shows 1,056 Medicare services from Dr. Mehta across 7 procedure codes in 2024, for 357 Medicare patients. Medicare paid $66,104 for them.

CMS counts 357 Medicare patients who saw Dr. Mehta in 2024. The largest group is 65 to 74, with 187 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 71, with 79% women.

In 2024, Dr. Mehta wrote 1,988 Medicare Part D claims for 387 patients. 90% of them were for generic drugs. CMS names the drug for 1,757 of them, across 29 drugs with 11 or more claims each, at $668,375 in total drug cost. In 2023, CMS named 1,544 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mehta for performance year 2024, reported through an alternative payment model (APM). Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mehta as offering telehealth.

Dmand AI links 46 papers to Dr. Mehta, published from 2011 to 2025. 2020 was the busiest year, with 7. The most frequent topics are High-Throughput Screening Assays, Alloys and Combinatorial Chemistry Techniques. Dr. Mehta has published most often in ACS Comb Sci. Dr. Mehta's most frequent co-authors are Stuart Campbell, MD, MS, Taylor Barnes, MD and Kai Chen, MD.

Dmand AI links Dr. Mehta to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 317 general payments to Dr. Mehta from 62 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $690.